Association Between Buprenorphine Treatment Gaps, Opioid Overdose, and Health Care Spending in US Medicare Beneficiaries With Opioid Use Disorder
Open Access
- 1 December 2022
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 79 (12) , 1173-1179
Abstract
Buprenorphine is a medication for opioid use disorder (MOUD) and a criterion standard treatment option for opioid use disorder (OUD). When taken consistently, buprenorphine reduces patient cravings for opioids, blunts the effects of opioids, and prevents opioid withdrawal.1-3 Previous research has found that at least 80% adherence to buprenorphine is needed to reduce the risk of relapse with opioids that can result in overdose,4 but issues such as poor treatment access and patient preferences can reduce adherence5-7; only 50% of patients adhere closely to their MOUD prescriptions.8 Low adherence to buprenorphine has previously been found to have severe consequences on patient health and spending.4,9-11 However, studies of MOUD nonadherence have primarily focused on nonadherent patient cohorts without looking at the immediate effects of gaps in treatment, variation across MOUD products and dosages, and have primarily considered Medicaid beneficiaries.9-11 Given the societal burden of the opioid epidemic,12 it is important to fill these knowledge gaps so health care professionals can better determine the short-term risks of nonadherence in patients and the relative benefits of different kinds of MOUD treatment and treatment intensity options.Keywords
This publication has 22 references indexed in Scilit:
- Substance Abuse and RehabilitationSubstance Abuse and Rehabilitation, 2020
- Medication-Assisted Treatment (MAT) for Opioid Addiction: Introduction to the Special IssueSubstance Use & Misuse, 2017
- Heterogeneity of nonadherent buprenorphine patients: subgroup characteristics and outcomes.2017
- The Association Between Buprenorphine Medication-Assisted Treatment Adherence And Health Care Service Utilization And CostsValue in Health, 2016
- Medication-Assisted Treatment of Opioid Use DisorderHarvard Review of Psychiatry, 2015
- Effectiveness of a computerized drug-monitoring program to detect and prevent adverse drug events and medication non-adherence in outpatient ambulatory care: study protocol of a randomized controlled trialTrials, 2015
- Factors Affecting Noncompliance With Buprenorphine Maintenance TreatmentJournal of Addiction Medicine, 2014
- Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine‐maintained heroin usersAddiction Biology, 2014
- PMH68 A LONGITUDINAL ANALYSIS OF THE EFFECT OF BUPRENORPHINE-MEDICATION ASSISTED TREATMENT (B-MAT) AND A STRUCTURED PATIENT SUPPORT PROGRAM ON B-MAT ADHERENCE IN A NATIONAL SAMPLE OF OPIOID DEPENDENT PATIENTSValue in Health, 2010
- Assessing Medication Adherence in the ElderlyDrugs & Aging, 2005